The major cardiac adverse events of dronedarone are bradycardia and prolongation of the QT interval. Similar to amiodarone, dronedarone inhibits creatinine secretion by the renal tubules, resulting in increased plasma creatinine levels; however, it has no effect on glomerular filtration and increases plasma levels of digoxin 1.7-2.5-fold. Dronedarone is primarily metabolized by the liver (CYP3A4) and has a half-life of 19 hours. Concomitant use with strong CYP3A4 inhibitors (e.g. ketoconazole and macrolide antibiotics) should be avoided to avoid compromising its efficacy. When it is combined with warfarin, it does not affect INR values. The guideline recommendation for oral dronedarone is 400 mg twice/day, and the dose for intravenous administration is unknown.